Comparative Pharmacology
Head-to-head clinical analysis: BREKIYA AUTOINJECTOR versus QFITLIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREKIYA AUTOINJECTOR versus QFITLIA.
BREKIYA (AUTOINJECTOR) vs QFITLIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interleukin-17A (IL-17A) antagonist; selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor, thereby reducing inflammatory responses.
QFITLIA is a monoclonal antibody that binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), inhibiting their interaction with the IL-12Rβ1 receptor and subsequent activation of cytokine signaling. This reduces inflammatory responses mediated by Th1 and Th17 pathways.
Adult: 200 mg subcutaneously once weekly. Administer via autoinjector. No loading dose required.
300 mg intravenously once daily for 3 days, then 150 mg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 23-26 days. This supports every 4-week subcutaneous dosing.
12 hours; prolonged to 24 hours in moderate renal impairment (CrCl 30-50 mL/min)
Primarily via reticuloendothelial system catabolism; Bimekizumab is a monoclonal antibody degraded into small peptides and amino acids. Renal and fecal excretion of intact drug is minimal (<1%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
TNF Inhibitor
TNF Inhibitor